[Effect of interferon-alpha on the prognosis of bone marrow transplantation in chronic myeloid leukemia].
To investigate whether prior interferon alfa (IFN-alpha) treatment affects the outcome of allogeneic bone marrow transplantation. The outcome of 85 patients with chronic myelogenous leukemia (CML) in first chronic phase received transplants from an HLA-identical sibling donor was analyzed. Of the 85 patients, 30 did not receive IFN-alpha, whereas 30, 15 and 10 patients received IFN-alpha 3 x 10(6) units 3-4 times per week for < 6, 6-12 and > 12 months before transplant combined with hydroxyurea and/or HA regimen (H: Harringtonine; A: Ara-C) respectively. Pretransplant IFN-alpha therapy for > or = 6 months was associated with an increased risk of severe (grade III-IV) acute graft-versus-host disease (GVHD) (P < 0.01) as compared to that in < 6 months or no IFN-alpha therapy. No influence of pretransplant IFN-alpha treatment on engraft, cGVHD, VOD, relapse and TRM (transplant-related mortality) was found. Survival rate of IFN-alpha therapy < 6 months group (90.0%) was higher than that of no IFN-alpha group (68.9%) or > 12 months group(60.0%) (P < 0.05). It was found that there was a trend towards an improved survival in the IFN-alpha < 6 months group. Pretransplant IFN-alpha therapy for > or = 6 months was associated with an increased risk of severe aGVHD.